March 2015. Volume 11. Number 1

Use of macrolides in mother and child increases the risk of infantile hypertrophic pyloric stenosis

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ. 2014;348:g1908.
Reviewers: Juanes de Toledo B1, Cuestas Montañés E2.
1EAP Collado Villalba. Collado Villalba. Madrid. España.
2Servicio de Pediatría y Neonatología. Hospital Privado. Centro Formador. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba. Córdoba. Argentina.
Correspondence: Blanca Juanes de Toledo. Email: blanca.juanesdetoledo@gmail.com
Reception date: 05/01/2015
Acceptance date: 23/01/2015
Publication date: 25/02/2015

Abstract

Authors' conclusion: treatment of young infants with macrolides is strongly associated with infantile hypertrophic pyloric stenosis and should therefore only be administered if potential treatment benefits outweigh the risk. Maternal use of macrolides during the first two weeks after birth was also associated with an increased risk of hypertrophic pyloric stenosis.

Reviewers' commentary: macrolides in newborn during the first two weeks after birth, is strogly associated with hypertrophic pyloric stenosis. Their use in mother on late pregnancy and during these first two weeks, also increases that risk, without clarifying the role of breastfeeding in the process.

How to cite this article

Juanes de Toledo B, Cuestas Montañés E. El uso de macrólidos en madres y neonatos aumenta en riesgo de estenosis hipertrófica de píloro. Evid Pediatr. 2015;11:7.

AVC | Critically appraised articles

Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ. 2014;348:g1908.
Reviewers: Juanes de Toledo B1, Cuestas Montañés E2.
1EAP Collado Villalba. Collado Villalba. Madrid. España.
2Servicio de Pediatría y Neonatología. Hospital Privado. Centro Formador. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba. Córdoba. Argentina.
Correspondence: Blanca Juanes de Toledo. Email: blanca.juanesdetoledo@gmail.com
Reception date: 05/01/2015
Acceptance date: 23/01/2015
Publication date: 25/02/2015

How to cite this article

Juanes de Toledo B, Cuestas Montañés E. El uso de macrólidos en madres y neonatos aumenta en riesgo de estenosis hipertrófica de píloro. Evid Pediatr. 2015;11:7.

References

  1. Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet. 1999:354:2101-5.
  2. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139:380-4.
  3. Sørensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schønheuder HC. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis. 2003;35:104-6.
  4. McAteer JP, Ledbetter DJ, Goldin AB. Role of bottle feeding in the etiology of hypertrophic pyloric stenosis. JAMA Pediatr. 2013;167:1143-9.
25/02/2015

Linked Comment